Fortress Biotech Inc - Company Profile
Powered by 
All the data and insights you need on Fortress Biotech Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Fortress Biotech Inc Strategy Report
- Understand Fortress Biotech Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Fortress Biotech Inc (Fortress Biotech), formerly Coronado Biosciences Inc, identifies, acquires, develops and commercializes marketed pharmaceuticals and development-stage pharmaceutical product candidates. The company provides business, scientific, regulatory, and legal support for advancing the products or product candidates of its partner firms. It is a marketing partner for various branded drugs indicated for the treatment of radiation dermatitis, severe acne, athlete’s foot, inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and other skin infections. Fortress Biotech is headquartered in Florida, the US.
Headquarters
United States of America
Address
1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida, 33154
Website
www.fortressbiotech.com
Telephone
1 781 6524500
No of Employees
186
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
FBIO (NASD)
Revenue (2022)
$84.5M
11.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
30%
(2022 vs 2021)
Market Cap*
$34.4M
Net Profit Margin (2022)
XYZ
37.2%
(2022 vs 2021)
* As of and is in US$
Fortress Biotech Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Marketed | In-Licensing Services | Qbrexza |
| Exelderm | Drug Development Services | Accutane |
| Ximino | Amzeeq | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In May, the company and uBriGene (Boston) Biosciences entered into a strategic manufacturing partnership to support MB-106 and future pipeline. |
| 2023 | Contracts/Agreements | In April, Aevitas Therapeutics signed an asset purchase agreement with 4D Molecular Therapeutics for the treatment of complement-mediated diseases. |
| 2022 | Contracts/Agreements | In December, Urica Therapeutics, Inc. expanded its license agreement with Fuji Yakuhin Co. Ltd. for the development of dotinurad to include the Middle East and North Africa and Turkey territories. |
Competitor Comparison
| Key Parameters | Fortress Biotech Inc | Sun Pharmaceutical Industries Ltd | Almirall SA | Mayne Pharma Group Ltd | Galderma Laboratories LP |
|---|---|---|---|---|---|
| Headquarters | United States of America | India | Spain | Australia | United States of America |
| City | Bay Harbor Islands | Mumbai | Barcelona | Adelaide | Fort Worth |
| State/Province | Florida | Maharashtra | - | South Australia | Texas |
| No. of Employees | 186 | 41,000 | 1,904 | 900 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lindsay A. Rosenwald | Chairman; Chief Executive Officer; President | Executive Board | 2013 | 67 |
| Michael S. Weiss | Executive Vice Chairman, Strategic Development | Executive Board | 2014 | 56 |
| Robyn M. Hunter | Chief Financial Officer | Senior Management | 2017 | 60 |
| David Jin | Head - Corporate Development; Chief Financial Officer | Senior Management | 2022 | 32 |
| Eric K. Rowinsky | Vice Chairman | Executive Board | 2010 | 66 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer